Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 38 Pancreatic Neoplasms 16 Colonic Neoplasms 12 Rectal Neoplasms 11 Stomach Neoplasms 9 Neoplasms 9 Neuroblastoma 8 Small Cell Lung Carcinoma 7 Rhabdomyosarcoma 7 Neoplasm Metastasis 7 Glioblastoma 7 Sarcoma, Ewing 6 Gastrointestinal Neoplasms 6 Central Nervous System Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Glioma 5 Sarcoma 4 Brain Neoplasms 4 Medulloblastoma 3 Intestinal Neoplasms 3 Gliosarcoma 3 Gastrointestinal Diseases 3 Esophageal Neoplasms 3 Digestive System Neoplasms 3 Digestive System Diseases 3 Astrocytoma 3 Advanced Solid Tumors 3 Recurrence 2 Rectal Diseases 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2

Interventions

pembrolizumab 6 aldesleukin 6 Cyclophosphamide 6 fludarabine phosphate 5 fludarabine 5 Nivolumab 4 durvalumab 3 Sorafenib 3 Radiotherapy 3 Filgrastim 3 Everolimus 3 Axitinib 3 Temozolomide 2 Peripheral Blood Stem Cell Transplantation 2 Isotretinoin 2 Ipilimumab 2 Interleukin-2 2 Interferon-alpha 2 Fluorouracil 2 Dexamethasone 2 Cyclosporine 2 Bevacizumab 2 vorolanib 1 tremelimumab 1 tocilizumab 1 talazoparib 1 spartalizumab 1 sargramostim 1 poly ICLC 1 palbociclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Kidney Neoplasms × Irinotecan × Clear all

NCT05384821 2026-03-18

MetroWilms

Centre Oscar Lambret

Phase 1/2 Recruiting

Kidney Neoplasms, Wilms Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡